Beam Therapeutics (BEAM) News Today

Rhumbline Advisers boosted its holdings in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 21.6% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 132,569 shares of the company's stock after ac

Shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) have been given a consensus recommendation of "Hold" by the thirteen research firms that are presently covering the stock, MarketBeat reports. Seven analysts have rated the stock with a hold rating and six have given a buy rating to

Stifel Nicolaus raised their price objective on Beam Therapeutics from $66.00 to $69.00 and gave the stock a "buy" rating in a report on Wednesday.

Beam Therapeutics (NASDAQ:BEAM) Trading Down 5.9%

Liontrust Investment Partners LLP acquired a new stake in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 80,000 shares of the company's stock, valued at approximately $

Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Equities researchers at HC Wainwright issued their Q3 2024 earnings per share estimates for shares of Beam Therapeutics in a report released on Thursday, August 22nd. HC Wainwright analyst P. Trucchio expects that the company will earn ($0.98)

Baillie Gifford & Co. trimmed its position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 17.1% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 623,640 shares of the company's stock after se

HC Wainwright restated a "buy" rating and set a $80.00 price target on shares of Beam Therapeutics in a research report on Thursday.

Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) has earned a consensus rating of "Hold" from the twelve ratings firms that are covering the company, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a hold recommendation and five have assigned a buy reco

Beam Therapeutics (NASDAQ:BEAM) Trading 4.2% Higher

Sumitomo Mitsui Trust Holdings Inc. lessened its stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 5.8% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,224,415 shares of the company's stock after sel

Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Analysts at Cantor Fitzgerald dropped their FY2024 earnings estimates for Beam Therapeutics in a report released on Wednesday, August 7th. Cantor Fitzgerald analyst R. Bienkowski now anticipates that the company will earn ($4.97) per share for

Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Equities researchers at Wedbush issued their FY2028 earnings per share estimates for shares of Beam Therapeutics in a research report issued on Tuesday, August 6th. Wedbush analyst D. Nierengarten anticipates that the company will post earnings

Beam Therapeutics (NASDAQ:BEAM - Get Free Report) released its earnings results on Tuesday. The company reported ($1.11) EPS for the quarter, topping the consensus estimate of ($1.13) by $0.02. Beam Therapeutics had a negative net margin of 37.33% and a negative return on equity of 15.46%. The company had revenue of $11.80 million during the quarter, compared to analysts' expectations of $14.18 million. During the same quarter last year, the business earned ($1.08) EPS. The business's revenue was down 41.3% on a year-over-year basis.

JPMorgan Chase & Co. raised their price target on shares of Beam Therapeutics from $45.00 to $48.00 and gave the company an "overweight" rating in a report on Wednesday.

Barclays dropped their price objective on Beam Therapeutics from $33.00 to $31.00 and set an "equal weight" rating on the stock in a report on Wednesday.

Royal Bank of Canada reiterated a "sector perform" rating and set a $27.00 price target on shares of Beam Therapeutics in a research note on Wednesday.

Wedbush reaffirmed an "outperform" rating and set a $57.00 price objective on shares of Beam Therapeutics in a report on Tuesday.

Virtu Financial LLC bought a new position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 26,486 shares of the company's stock, valued at a

Beam Therapeutics (NASDAQ:BEAM) Trading Down 9.2%

Price T Rowe Associates Inc. MD lifted its position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 3,137.7% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,246,189 shares of the company's stock aft

Vanguard Group Inc. raised its position in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 5.8% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 7,578,768 shares of the company's stock after buying an additional 413,892 shares during the quarter. Vangua

Redmile Group LLC increased its stake in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 31.5% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,879,617 shares of the company's stock after purchasin